In today’s rapidly evolving environment, drug and device companies face new challenges to deliver better patient outcomes at lower costs. KPMG is a leading advisor to the Life Sciences industry, providing a wide range of services to help organizations grow their business, enhance performance, and manage risks.
We offer a market-leading portfolio of methodologies, tools and services to assist Life Science companies in the following areas:
Independent audit and assurance services
Analyses and assessments on R&D effectiveness
Transactions (due diligence, integration and separation)
Tax compliance and governance
Value chain analysis
Risk management and regulatory compliance
Disruptive technologies and advanced analytics
Contact
KPMG Basel
Viaduktstrasse 42
PO Box 3456
4002 Basel
Tel. +41 58 249 91 91
Fax +41 58 249 91 23
KPMG Life Sciences Team Switzerland: https://home.kpmg.com/ch/en/home/industries/life-sciences.html
Patient-driven drug pricing, the uncertain future of Switzerland’s tax regime, and new business models for life science innovators in a changing global market are just a few of the topics…
After seven years at the helm of the pharma industry’s biggest global trade group, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Thomas Cueni is retiring. Having played a…
Gavi, the world’s largest vaccine-focused public-private partnership has a new leader. Pakistani Senator Dr Sania Nishtar has officially assumed the role of CEO following a period of leadership uncertainty for…
The biggest pharma news from Switzerland, including the industry’s cautious reaction to a new free trade deal with India; the drop in Roche’s share prices; Novartis’ acquisiton of MorphoSys, and…
For the Swiss Agency for Therapeutic Products (Swissmedic), one of the world’s leading regulatory authorities, 2023 was an important year. Not only did the agency gain recognition from the World…
Obesity is pharma’s new El Dorado. Following the spectacular market success and sky-high sales projections of next-generation obesity treatments, many actors – both large and small – are looking to…
Every year, the world’s top business and political leaders converge on the ski village of Davos, Switzerland for the World Economic Forum meeting. Read on for some of the key…
As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on biosimilars. Having already launched a version of AbbVie’s blockbuster arthritis treatment…
Ahead of the 78th session of the United Nations General Assembly (UNGA78), IFPMA Director General Thomas Cueni underscores the need for pandemic preparedness plans to support innovation and equity. Global…
Regular contributor Brendan Shaw* casts his eye over the recently announced 2023 WHO Essential Medicines List, how it reflects growing pharmaceutical innovation, and why maintaining a ‘seat at the table’…
Following the appointment of new boards at the US innovative pharma industry body PhRMA, and its European counterpart EFPIA, it is global group the IFPMA’s turn to reveal a new…
At this year’s Swiss Biotech Day, the Swiss Biotech Association celebrated its 25 years of existence and proved the ability of the sector to weather geopolitical disruptions and funding challenges…
Brendan Shaw examines the protracted efforts of global stakeholders to come together around a global pandemic treaty and outlines the benefits of constructive engagement on the part of the pharmaceutical…
See our Cookie Privacy Policy Here
